anaplastic lymphoma kinase Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Anaplastic lymphoma kinase (ALK) fusion in non-small cell lung cancer (NSCLC)
was first described by Soda and colleagues in 2007. Using a retrovirus-mediated
complementary DNA expression system, they discovered that a small inversion in
the chromosome 2p results in a product consisting of portions of the echinoderm
microtubule-associated protein-like 4 (EML4) gene and the ALK gene. The fusion
had transforming properties in mouse 3T3 fibroblast model and was targetable by
ALK inhibitor WHI-P154 [1].
anaplastic lymphoma kinase Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
